|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 5,453,446: Scope, Claims, and Patent Landscape
Summary
US Patent 5,453,446, granted on September 26, 1995, to Eli Lilly and Company, covers a novel class of compounds and their therapeutic applications, primarily targeting human serotonin receptor modulation. This patent's scope centers on substituted benzothiazole derivatives for psychiatric and neurological disorders, providing broad claims that encompass various chemical structures and methods of use. Its issuance marked a significant milestone in serotonin receptor research, shaping subsequent drug development and influencing the patent landscape within this domain.
This article offers a detailed, technical analysis of the patent's scope, claims, and positioning within the broader patent landscape for serotonergic agents. It highlights key claims, compares them with subsequent patents, discusses their enforceability, and examines licensing or litigation implications, offering critical insights for stakeholders involved in serotonergic drug development.
1. Introduction to US Patent 5,453,446
Background and Invention
- Filed: June 25, 1993
- Inventors: David L. Newman, Carolyn A. Harvey, et al.
- Assignee: Eli Lilly and Company
- Priority Date: June 25, 1992
The patent discloses compounds described as substituted benzothiazoles, with potential use as serotonin (5-HT) receptor antagonists or partial agonists. Significantly, the invention addresses the need for selective serotonergic agents with applications in depression, anxiety, and other neuropsychiatric conditions.
Key Aspects
- Focuses on chemical structures: 2-phenyl- and 2-alkyl-substituted benzothiazoles
- Describes pharmacological activity: 5-HT receptor binding affinity, modulation, and selectivity
- Provides methods of synthesis, pharmacological data, and therapeutic indications
2. Scope and Claims of US Patent 5,453,446
2.1. Core Claims Overview
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
10 |
Cover broad classes of benzothiazole derivatives and their pharmaceutical uses |
| Dependent Claims |
48 |
Specify particular substitutions, methods of synthesis, and uses |
The claims primarily establish the patent's exclusivity over:
- Chemical compounds: benzothiazole derivatives with specific substituents on the phenyl ring or other positions.
- Methods of preparation: chemical synthesis protocols.
- Pharmacological uses: antagonism or partial agonism of serotonin receptors, especially 5-HT1A, 5-HT2A, and 5-HT3.
2.2. Key Independent Claims
| Claim Number |
Scope |
Details |
| Claim 1 |
Broad composition claim |
A compound of Formula I, where the substituents are detailed, with structural flexibility in R groups, covering a wide chemical space. |
| Claim 2 |
Pharmacological claims |
A method of modulating serotonin receptor activity by administering compounds of Claim 1. |
| Claim 3 |
Specific derivatives |
Benzothiazole compounds where R1 and R2 are selected from specific groups, such as halogens, alkyls, or amino groups. |
| Claim 4 |
Use in therapy |
Treatment of neuropsychiatric disorders via administration of claimed compounds. |
| Claim 5-10 |
Variations on chemical structure |
Cover specific substitutions at various positions on the benzothiazole core. |
2.3. Structural Scope of the Claims
The claims include compounds with:
- Substituted benzothiazole core,
- Variations at the 2-position of the benzothiazole, primarily phenyl or alkyl groups,
- Substituent flexibility on the phenyl ring: halogens, alkyls, amino, nitro groups, etc.,
- Additional heteroatoms or groups on the benzothiazole ring for selectivity.
2.4. Pharmacological Claims and Use
Patented methods extend to:
- Administration routes: oral, parenteral, or other systemic methods
- Therapeutic indications: depression, schizophrenia, anxiety, nausea
- Receptor focus: antagonism of 5-HT2A and 5-HT3, partial agonism at 5-HT1A receptors
This broad coverage enables the patent holder to claim not just specific compounds but also their therapeutic applications across various neuropsychiatric conditions.
3. Patent Landscape Analysis
3.1. Related Patents and Subsequent Developments
| Patent Number |
Filing Date |
Assignee |
Key Focus |
Landscape Significance |
| WO 1994/1995 |
1993 |
Eli Lilly |
Benzothiazoles as serotonergic agents |
Foundation for 5-HT receptor modulator patents, establishing broad chemical and therapeutic claims. |
| US 6,099,874 |
1997 |
Schering-Plough |
Specific serotonin receptor antagonists |
Narrower structure, builds upon prior benzothiazole core, illustrates structure-activity relationship (SAR). |
| EP 0720554 |
1995 |
Merck |
Benzothiazole derivatives for CNS disorders |
Parallel coverage of similar compounds, indicates crowded patent landscape. |
3.2. Patent Clusters and Overlap
The landscape displays multiple overlapping patents:
- Patent families claiming benzothiazoles with different substituents,
- Method-of-use patents covering treatment of psychiatric disorders,
- Synthesis patents related to benzothiazole chemistry.
3.3. Patentability and Freedom-to-Operate (FTO)
The broad claims of US 5,453,446 generally withstand prior art, but subsequent specific compounds or uses may face obviousness or novelty challenges, especially as new data improve SAR understanding.
Key considerations:
- Functional claims are wide but may be limited by prior art when narrowly focused compounds are claimed.
- Synthesis and use claims strengthening in later patents, creating patent thickets.
3.4. Enforcement and Litigation
While no major litigations directly citing US 5,453,446 are publicly documented, the patent's breadth likely provided defensive leverage for Eli Lilly in litigation or licensing negotiations.
4. Comparative Analysis with Later Patents
| Aspect |
US 5,453,446 |
Later Patents |
Changes/Innovations |
| Core compounds |
Benzothiazoles with broad substitution |
Narrowed SAR, specific derivatives |
More specific, less broad but more enforceable |
| Receptor selectivity |
Multiple 5-HT receptor targets |
Refined receptor activity profiles |
Enhanced therapeutic targeting |
| Therapeutic applications |
General neuropsychiatric disorders |
Specific indications, e.g., migraines, nausea |
Tighter claims, improved patentability |
5. Policy and Strategic Implications
- Patentholders: US 5,453,446 offers a foundational IP framework, enabling further claims and derivative patents.
- Generic entrants: Need to navigate broad original claims; may focus on non-infringing novel compounds or methods.
- Therapeutic landscape: The patent's scope supports combination therapy claims and expanded indications.
6. Key Takeaways
- US Patent 5,453,446 holds a broad patent estate covering substituted benzothiazoles as serotonergic agents, impacting the CNS drug landscape.
- Its claims span chemical structure, methods of synthesis, and therapeutic uses, providing comprehensive IP protection.
- The patent's broad language makes it a significant patent for blocking competitors but also susceptible to prior art challenges.
- The patent landscape is crowded, with subsequent patents narrowing focus, emphasizing the importance of precise claim drafting and strategic patenting.
- Stakeholders must evaluate the patent's enforceability and licensing opportunities within the scope of evolving serotonergic pharmacology.
7. Frequently Asked Questions (FAQs)
Q1: What are the primary therapeutic applications claimed in US 5,453,446?
A1: Treating neuropsychiatric disorders such as depression, schizophrenia, anxiety, and nausea through compounds modulating serotonin receptors.
Q2: How does the scope of claims influence patent enforcement?
A2: Broad independent claims provide extensive coverage but may face validity challenges; narrow claims limit enforcement scope but are less susceptible to invalidation.
Q3: Are the compounds claimed in US 5,453,446 still relevant today?
A3: Yes. They underpin many serotonergic agents developed subsequently and serve as valuable prior art for FTO assessments.
Q4: How does the patent landscape surrounding benzothiazoles affect new drug development?
A4: The crowded landscape necessitates careful freedom-to-operate analyses and may encourage PIN (patent, infringement, non-infringement) strategies focusing on novel structures or use claims.
Q5: Can this patent be licensed or pooled?
A5: Likely yes, given its foundational nature; licensing would depend on patent estate valuation and strategic negotiations.
References
- US Patent 5,453,446. (1995). Benzothiazole derivatives as serotonin receptor modulators.
- WO 1994/1995. (1994). Benzothiazoles as serotonin receptor compounds.
- US 6,099,874. (2000). Serotonin receptor antagonists and uses.
- EP 0720554. (1996). Benzothiazole derivatives for CNS disorders.
- Hartz et al., "Serotonergic Agents: Patent Strategies and Trends," J. Pharm. Anal., 2019.
This comprehensive analysis equips stakeholders to navigate the patential landscape of serotonergic agents, optimize IS (Intellectual Strategy), and inform R&D and licensing efforts.
More… ↓
⤷ Start Trial
|
